详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Gut microbiota-dependent phenylacetylglutamine in cardiovascular disease: current knowledge and new insights

96| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C

作者：

单位： [1]Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. [2]Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, 430030, China.

出处：

DOI：

ISSN：

关键词： PAGln cardiovascular disease gut microbiota uremic metabolite biomarker

摘要：

Phenylacetylglutamine (PAGln) is an amino acid derivate that comes from the amino acid phenylalanine. There are increasing studies showing that the level of PAGln is associated with the risk of different cardiovascular diseases. In this review, we discussed the metabolic pathway of PAGln production and the quantitative measurement methods of PAGln. We summarized the epidemiological evidence to show the role of PAGln in diagnostic and prognostic value in several cardiovascular diseases, such as heart failure, coronary heart disease/atherosclerosis, and cardiac arrhythmia. The underlying mechanism of PAGln is now considered to be related to the thrombotic potential of platelets via adrenergic receptors. Besides, other possible mechanisms such as inflammatory response and oxidative stress could also be induced by PAGln. Moreover, since PAGln is produced across different organs including the intestine, liver, and kidney, the cross-talk among multiple organs focused on the function of this uremic toxic metabolite. Finally, the prognostic value of PAGln compared to the classical biomarker was discussed and we also highlighted important gaps in knowledge and areas requiring future investigation of PAGln in cardiovascular diseases.© 2024. The Author(s).

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 3 区医学：研究与实验 4 区肿瘤学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区医学：内科 2 区医学：研究与实验 2 区肿瘤学

JCR分区：

出版当年[2022]版：

Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 ONCOLOGY

最新[2023]版：

Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 ONCOLOGY

影响因子： 3.9 最新[2023版] 5.4 最新五年平均 8.1 出版当年[2022版] 6.4 出版当年五年平均 9.927 出版前一年[2021版] 3.9 出版后一年[2023版]

第一作者：

第一作者单位： [1]Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. [2]Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, 430030, China.

通讯作者：

通讯机构： [1]Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. [2]Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, 430030, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Present and Future: Crosstalks Between Polycystic Ovary Syndrome and Gut Metabolites Relating to Gut Microbiota [2]Enterochromaffin Cells: Sentinels to Gut Microbiota in Hyperalgesia? [3]Gut Microbiota and Metagenomic Advancement in Digestive Disease [4]Fecal microbiota transplantation induces remission of infantile allergic colitis through gut microbiota re-establishment [5]The role of gut microbiota and metabolites in cancer chemotherapy [6]Intermittent Fasting on Neurologic Diseases: Potential Role of Gut Microbiota [7]Superior cervical ganglionectomy alters gut microbiota in rats [8]The role of gut microbiota in immune checkpoint inhibitor therapy [9]Depletion of Gut Microbiota Impairs Gut Barrier Function and Antiviral Immune Defense in the Liver [10]Gut-muscle axis and sepsis-induced myopathy: The potential role of gut microbiota